Welcome to our dedicated page for Cel-Sci Corporation news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on Cel-Sci Corporation stock.
Cel-Sci Corporation (symbol: CVM) is at the forefront of biotechnology, dedicated to advancing immunotherapy solutions for cancer and infectious diseases. Established in 1983 and headquartered in Vienna, Virginia, Cel-Sci is committed to harnessing the power of the human immune system to combat a variety of health challenges.
The company's leading investigational immunotherapy, Multikine (Leukocyte Interleukin, Injection), is currently in Phase III clinical trials for the treatment of head and neck cancer. This breakthrough therapy aims to improve survival rates by leveraging the body's natural defenses.
In addition to Multikine, Cel-Sci is pioneering the Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process designed to stimulate the immune system to fight bacterial, viral, and parasitic infections, and conditions such as autoimmune diseases, allergies, transplantation rejections, and cancer. Their innovative pipeline includes LEAPS-H1N1-DC, as well as product candidates CEL-2000 and CEL-4000 for the treatment of rheumatoid arthritis. The company is also developing LEAPS COV-19 to address the COVID-19 pandemic, in collaboration with the University of Georgia's Center for Vaccines and Immunology.
Cel-Sci's core capabilities extend to drug discovery, research, development, and the manufacturing of complex biological substances. The company's multifaceted approach not only targets cancer but also seeks to provide solutions for a wide range of infectious and autoimmune diseases. By focusing on these areas, Cel-Sci aims to deliver groundbreaking treatments that can significantly improve patient outcomes and quality of life.
Recent achievements and ongoing projects underscore Cel-Sci's commitment to innovation and excellence in the biotechnology field. The company's robust pipeline and strategic collaborations position it as a significant player in the quest for effective immunotherapies, offering hope to millions affected by cancer and other debilitating conditions.
Stay updated with the latest news and developments from Cel-Sci Corporation to track their progress and breakthroughs in cancer and immunotherapy research.
CEL-SCI Corporation (NYSE American: CVM) has successfully conducted a pre-submission meeting with Health Canada to discuss regulatory pathways for its investigational immunotherapy, Multikine. The company aims to secure marketing approval in Canada and other countries while preparing its Biologics License Application for the U.S. FDA. Health Canada advised CEL-SCI on pursuing a Notice of Compliance with Conditions policy, enabling earlier access for patients with serious conditions. Results from the Phase 3 IT-MATTERS study show Multikine's significant potential in improving survival rates for head and neck cancer patients.
CEL-SCI Corporation (CVM) recently presented pivotal Phase 3 study data at the 10th European Congress on Head & Neck Oncology. The study focused on its investigational therapy, Multikine, for newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Key findings show that Multikine added to standard care significantly improves overall survival rates: 65.3% for treated patients versus 49.7% for controls after five years. The company plans to submit a Biologics License Application to the FDA for regulatory approval based on results involving 352 patients. The study highlights the potential of Multikine in enhancing treatment outcomes for this patient population.
CEL-SCI Corporation (NYSE American: CVM) announced that it will present new data from its pivotal Phase 3 study on March 8, 2023, at the 10th European Congress on Head & Neck Oncology in Lisbon, Portugal. The study, the largest ever for newly diagnosed locally advanced squamous cell carcinoma of the head and neck, involved 928 patients and aimed to assess the investigational product Multikine before standard treatments. Multikine, which received Orphan Drug designation from the FDA, seeks to harness the immune system's potential before conventional therapies. A summary of the findings will be published after the presentation.
CEL-SCI Corporation (AMEX: CVM) announced its financial results for the quarter ending
CEL-SCI Corporation (NYSE American: CVM) reported fiscal year 2022 results, focusing on the submission of a Biologics License Application for its product, Multikine, targeting advanced primary head and neck cancer. The Phase 3 trial showed significant survival benefits, with a median overall survival improvement of 46.5 months. Financially, the company had a net operating loss of $36.1 million. As of September 30, 2022, CEL-SCI was holding $22.7 million in cash. Despite challenges, the company aims to expedite its regulatory submission and leverage positive trial outcomes.
CEL-SCI Corporation (NYSE American: CVM) announced significant progress regarding its investigational drug Multikine for treating locally advanced primary squamous cell carcinoma of the head and neck. The Phase 3 trial showed a median overall survival improvement of 46.5 months, with 62.7% of patients alive after five years. Multikine is positioned as a neoadjuvant therapy, unlike competitors’ treatments, which are for recurrent tumors. Despite challenges due to limited resources compared to larger firms, the company remains committed to advancing Multikine’s approval for patient benefit.
FAQ
What is the current stock price of Cel-Sci Corporation (CVM)?
What is the market cap of Cel-Sci Corporation (CVM)?
What is Cel-Sci Corporation's main focus?
What is Multikine?
What is the LEAPS technology?
What other products is Cel-Sci developing?
Where is Cel-Sci Corporation headquartered?
When was Cel-Sci Corporation founded?
With whom does Cel-Sci collaborate for LEAPS COV-19?
What areas does Cel-Sci's research cover?
What are CEL-2000 and CEL-4000?
What distinguishes Cel-Sci in the biotechnology sector?
